The biotech industry experienced its share of stormy weather this year, from budget cuts and the fiscal cliff to Prometheus v. Mayo and a drop in VC funds, but there were a few sunny days here and there: FDA finally issued its draft guidance on the development and approval of biosimilar drugs, and two new obesity drugs were approved by FDA, the first in more than a decade. (For more on all of the above developments, click here.) So, what does your industry forecast look like for 2013—clear sailing ahead, or should sailors take warning?
Poll Question:
What kind of future do you predict for the biotech industry in 2013?
Stormy
97
Cloudy
268
Sunny
224
